Re: We are excited to present the latest data from our RGLS4326 program for the treatment of ADPKD," commented Jay Hagan, President and Chief Executive Officer of Regulus. "This year's conference is an opportune occasion to share with the PKD community ou
"Rgls back (at $1.95)"
Minor detail, but $0.95, ha. We will see. I could be completely wrong. Past performance is no indication of future performance.